Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Brain Neoplasms × Losartan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Pancreatic Neoplasms 2 Stomatitis 1 Radiation Fibrosis Syndrome 1 Peripheral Nervous System Diseases 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Inflammation 1 Hypertension 1 Glioblastoma 1 Fibrosis 1 Fallopian Tube Neoplasms 1 Coronavirus Infections 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Camurati-Engelmann Syndrome 1 COVID-19 1 Brain Neoplasms 1

Interventions

Temozolomide 64 Bevacizumab 53 Radiotherapy 36 Radiosurgery 26 Carboplatin 21 pembrolizumab 15 Etoposide 15 Nivolumab 14 Irinotecan 14 Magnetic Resonance Spectroscopy 13 Cisplatin 13 Carmustine 13 Ipilimumab 12 Erlotinib Hydrochloride 12 Cyclophosphamide 12 Pemetrexed 11 Surgical Procedures, Operative 10 Capecitabine 10 Topotecan 9 Lapatinib 9 Thalidomide 8 Aminolevulinic Acid 8 Trastuzumab 7 Lomustine 7 Imatinib Mesylate 7 Gefitinib 7 Filgrastim 7 trametinib 6 osimertinib 6 encorafenib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03951142 2023-11-01

ImPRESS

Oslo University Hospital

Phase 2 Unknown

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡